| Literature DB >> 33010399 |
Alice Melocchi1, Francesco Briatico-Vangosa2, Marco Uboldi3, Federico Parietti4, Maximilian Turchi5, Didier von Zeppelin6, Alessandra Maroni3, Lucia Zema7, Andrea Gazzaniga3, Ahmed Zidan8.
Abstract
3D printing, and particularly fused deposition modeling (FDM), has rapidly brought the possibility of personalizing drug therapies to the forefront of pharmaceutical research and media attention. Applications for this technology, described in published articles, are expected to grow significantly in 2020. Where are we on this path, and what needs to be done to develop a FDM 2.0 process and make personalized medicines available to patients? Based on literature analysis, this manuscript aims to answer these questions and highlight the critical technical aspects of FDM as an emerging technology for manufacturing safe, high-quality personalized oral drug products. In this collaborative paper, experts from different fields contribute strategies for ensuring the quality of starting materials and discuss the design phase, printer hardware and software, the process, the environment and the resulting products, from the perspectives of both patients and operators.Entities:
Keywords: 3D printing; Drug product fabrication; Fused deposition modeling; Quality; Safety
Mesh:
Substances:
Year: 2020 PMID: 33010399 DOI: 10.1016/j.ijpharm.2020.119901
Source DB: PubMed Journal: Int J Pharm ISSN: 0378-5173 Impact factor: 5.875